TRUBAR INC (TRBR.CA) Stock Fundamental Analysis
Canada - TSX-V:TRBR - CA89778A1003 - Common Stock
0.9 CAD
+0.04 (+4.65%)
TRBR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. TRBR may be in some trouble as it scores bad on both profitability and health. TRBR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TRBR has reported negative net income.
TRBR had a positive operating cash flow in the past year.
TRBR had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: TRBR reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of TRBR (-1.47%) is better than 64.71% of its industry peers.
TRBR's Return On Equity of -22.83% is in line compared to the rest of the industry. TRBR outperforms 47.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.47% | ||
| ROE | -22.83% | ||
| ROIC | N/A |
ROA(3y)-53.1%
ROA(5y)-47.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TRBR has a Gross Margin of 29.78%. This is comparable to the rest of the industry: TRBR outperforms 52.94% of its industry peers.
TRBR's Gross Margin has declined in the last couple of years.
TRBR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.17%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TRBR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TRBR has been increased compared to 1 year ago.
TRBR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TRBR has been reduced compared to a year ago.
2.2 Solvency
TRBR has an Altman-Z score of -0.47. This is a bad value and indicates that TRBR is not financially healthy and even has some risk of bankruptcy.
TRBR has a Altman-Z score (-0.47) which is in line with its industry peers.
The Debt to FCF ratio of TRBR is 6.61, which is on the high side as it means it would take TRBR, 6.61 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of TRBR (6.61) is better than 79.41% of its industry peers.
TRBR has a Debt/Equity ratio of 2.69. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of TRBR (2.69) is worse than 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.69 | ||
| Debt/FCF | 6.61 | ||
| Altman-Z | -0.47 |
ROIC/WACCN/A
WACC8.98%
2.3 Liquidity
TRBR has a Current Ratio of 0.90. This is a bad value and indicates that TRBR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of TRBR (0.90) is worse than 79.41% of its industry peers.
A Quick Ratio of 0.74 indicates that TRBR may have some problems paying its short term obligations.
TRBR's Quick ratio of 0.74 is on the low side compared to the rest of the industry. TRBR is outperformed by 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 98.61% over the past year.
Looking at the last year, TRBR shows a very negative growth in Revenue. The Revenue has decreased by -42.52% in the last year.
TRBR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.58% yearly.
EPS 1Y (TTM)98.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.93%
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y42.58%
Revenue growth 5YN/A
Sales Q2Q%3.75%
3.2 Future
TRBR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.10% yearly.
Based on estimates for the next years, TRBR will show a very strong growth in Revenue. The Revenue will grow by 35.80% on average per year.
EPS Next Y-166.67%
EPS Next 2Y-29.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year34.43%
Revenue Next 2Y35.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TRBR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRBR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TRBR indicates a somewhat cheap valuation: TRBR is cheaper than 67.65% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.24 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TRBR's earnings are expected to decrease with -29.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.1%
EPS Next 3YN/A
5. Dividend
5.1 Amount
TRBR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:TRBR (10/2/2025, 7:00:00 PM)
0.9
+0.04 (+4.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners20.7%
Ins Owner ChangeN/A
Market Cap97.01M
Analysts84
Price Target2.3 (155.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-166.67%
EPS NY rev (3m)-366.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.79%
Revenue NY rev (3m)-6.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.52 | ||
| P/FCF | 61.24 | ||
| P/OCF | 60.18 | ||
| P/B | 42.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.01
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.01
FCFY1.63%
OCF(TTM)0.01
OCFY1.66%
SpS0.59
BVpS0.02
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.47% | ||
| ROE | -22.83% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.78% | ||
| FCFM | 2.48% |
ROA(3y)-53.1%
ROA(5y)-47.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.17%
GM growth 5YN/A
F-Score5
Asset Turnover1.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.69 | ||
| Debt/FCF | 6.61 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.3% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | -0.47 |
F-Score5
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)2.76%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.93%
EPS Next Y-166.67%
EPS Next 2Y-29.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y42.58%
Revenue growth 5YN/A
Sales Q2Q%3.75%
Revenue Next Year34.43%
Revenue Next 2Y35.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y73.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-62.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y133.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y134.46%
OCF growth 3YN/A
OCF growth 5YN/A